Fisher & Paykel Healthcare (FPH) Investor Presentation summary

Event overview and structure

• Investor event held on 23 July 2025 in Melbourne, focused on clinical practice change and product innovation.

• Sessions included guided discussions and Q&A with leading clinicians and company executives.

• Rotations covered Optiflow & NIV in the ED, Neonatal Care, Optiflow on the Ward, and Anaesthesia.

• Executive management participated in Q&A, providing strategic and operational insights.

Product innovation and clinical evidence

• High-flow therapy product line has evolved through multiple generations, with pivotal RCTs supporting clinical use.

• Over 8,000 global continuous improvement suggestions and 3,900 initiatives executed in FY25.

• Annual publications on nasal high flow therapy have grown significantly, reflecting increased clinical adoption.

• 193 ongoing clinical trials for Anaesthesia Optiflow across 25+ countries as of June 2025.

• Systematic reviews and meta-analyses highlight nasal high flow's effectiveness in extending safe apnea time during anaesthesia.

Market opportunity and growth aspirations

• Total addressable market estimated at 150+ million hospital patients and 100+ million homecare patients.

• Portfolio includes invasive/noninvasive ventilation, respiratory support, anaesthesia, and sleep apnea therapies.

• Long-term aspiration is to achieve 12%+ annual revenue growth in constant currency, aiming to double revenue every 5-6 years.

• Gross margin trajectory and continuous improvement in manufacturing remain key focus areas.